Europe (WHO region) vs Jordan: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Jordan
100.0%
in 2024
Europe (WHO region) rank
2nd
Jordan rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Jordan
How they compare
Jordan currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Jordan's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 6 times across 20 shared years of data; in 2005 it was Jordan ahead.
Europe (WHO region) ranks 2nd and Jordan ranks 1st of 11 groups.
Across the 3 decades both report, Europe (WHO region) averaged higher in 2 and Jordan in 1.
Head to head by decade
| Decade | Europe (WHO region) | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 20.2% | 87.0% | 66.8% | Jordan |
| 2010s | 57.7% | 36.5% | 21.2% | Europe (WHO region) |
| 2020s | 93.8% | 58.4% | 35.4% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Jordan?
- Jordan, at 100.0% against 90.0% in Europe (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Jordan?
- 10.0%, with Jordan ahead.
- How many years of comparable data are there for Europe (WHO region) and Jordan?
- 20 years are reported by both, from 2005 to 2024.
- How do Europe (WHO region) and Jordan rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Jordan ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.